Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3 were exercised, corresponding to 100.0 percent of the total …
